tbuckley/cabot-search huggingface dataset:
Serum chemokines and cytokines in CLL patients treated with duvelisib, a PI3K-δ,γ inhibitor.
Authors: Mark Douglas, Kerstin Allen, Jennifer Sweeney, Susan Mary O'Brien, Ian Flinn, Steven M. Horwitz, John C. Byrd, Manish R. Patel, Brad S. Kahl, Francine M. Foss, Pierluigi Porcu, Virginia Kelly, Howard Stern
Journal: Journal of Clinical Oncology (2015)

7072 Background: PI3K-δ and PI3K-γ play complementary roles in malignant B-cells and the tumor microenvironment (TME). Inhibition of PI3K-δ blocks cytokine-mediated CLL proliferation, while inhibition of PI3K-γ blocks M2 macrophage polarization and T-cell migration in vitro. Duvelisib, an oral PI3K-δ,γ inhibitor, has shown clinical activity in a phase 1 study in patients (pts) with advanced hematologic malignancies (Study IPI-145-02), including pts with relapsed/refractory (R/R) CLL (O’Brien, ASH 2014). Methods: Serum from 52 pts with R/R CLL and 30 healthy subjects (HS) was analyzed for 72 analytes (cytokines, chemokines, and matrix metalloproteinases) using Luminex xMAP technology at baseline, Cycle 1 Day 8 (C1D8), C2D1, and C3D1. Median change from baseline was analyzed for statistical significance using a paired t-test with Bonferroni correction for multiple hypotheses; threshold for reduction was ≤ 50% of baseline and for increase was ≥ 150% of baseline. Comparison between CLL and HS utilized a 2-sample t-test with Bonferroni correction. Results: Following treatment with duvelisib, the median serum levels of 12 analytes decreased to ≤ 50% of baseline (p < 0.0002) by C1D8. These included CCL1, CCL3, CCL4, CCL17, CCL22, CXCL10, CXCL13, IL-6, IL-10, IL-12p40, MMP-9 & TNFα. All of these were significantly elevated (p < 0.0042) at baseline in CLL pts compared to HS and reduced towards normal range following duvelisib treatment. In addition, MMP1 was the only analyte for which median serum levels increased above the threshold of ≥ 150% of baseline (p < 0.0002). Together, these 13 analytes were further explored for potential associations with clinical efficacy. TNFα was significantly elevated (p < 0.0013) at C2D1 & C3D1 in pts who did not exhibit a nodal response. Conclusions: Most of the analytes reduced following duvelisib treatment are known to be involved in the communication between CLL cells and the TME. Furthermore, one of these analytes (TNFα) exhibited elevated levels at C2D1 and C3D1 in pts who did not achieve a nodal response. Together, these data indicate that modulation of the TME via PI3K-δ,γ inhibition may be an important mechanism of action in supporting clinical activity of duvelisib in patients with CLL. Clinical trial information: NCT01476657.
SEX DIFFERENCES IN REVASCULARIZATION AND IN-HOSPITAL OUTCOMES OF NON-ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION IN THE UNITED STATES
Authors: Tanush Gupta, Dhaval Kolte, Sahil Khera, Pedro Villablanca, Kashish Goel, Wilbert Aronow, Jose Wiley, Anna Bortnick, Robert Pyo, Julio Panza, Charanjit Rihal, Mark Menegus, Ernest Monrad, Gregg Fonarow, Mario Garcia, Deepak Bhatt
Journal: Journal of the American College of Cardiology (2017)
Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars: A physician survey in the United States and emerging markets.
Authors: Philip Edward Lammers, Carmen Criscitiello, Giuseppe Curigliano, Ira Allen Jacobs
Journal: Journal of Clinical Oncology (2014)

610 Background: Biologics, such as trastuzumab, are an important part of oncology treatment paradigms, although access to such therapies is a challenge in emerging markets and in certain areas of more developed countries such as the United States (US). Biosimilars have the potential to increase access to biologic therapies by offering a comparable but more affordable alternative relative to the innovator biologic. This study examined access to trastuzumab and identified barriers to its use in HER2+ breast cancer patients in the US, Mexico (MEX), Turkey (TUR), Russia (RUS), and Brazil (BRZ). The study also examined whether availability of a biosimilar to trastuzumab would improve access to, and use of, HER2 monoclonal antibody therapy. Methods: Medical oncologists (N=500) completed a blinded survey examining their use of trastuzumab. Results: Across all countries, oncologists reported “not so often”, “rarely”, or “never” using trastuzumab in a neoadjuvant (27%), adjuvant (8%), or metastatic (8%) setting. Common barriers to the use of trastuzumab were related to insurance coverage, drug availability, cost to the patient, treatment guidelines, and patient comorbidities. Oncologists also reported having had to cancel or delay treatment with trastuzumab due to reimbursement issues (Overall=31%, US=10%, BRZ=48%, MEX=37%, TUR=16%, RUS=76%). Overall, 45% of oncologists reported that they would increase the use of HER2 monoclonal antibody therapy if a lower cost biosimilar to trastuzumab was available, including 29% of US oncologists. This percentage was higher in BRZ (53%), MEX (63%), and RUS (81%). Oncologists reported that use would increase across all treatment settings. Conclusions: The availability of a trastuzumab biosimilar may increase use of HER2 monoclonal antibody therapy in the breast cancer arena across all treatment settings in the US and, to an even greater extent, in the emerging markets of RUS, MEX, and BRZ. A biosimilar could provide benefit to patients who currently do not receive trastuzumab, or receive less than optimal treatment, due to insurance coverage or cost issues related to such treatment. Sponsored by Pfizer Inc.
Breast cancer: Updated vaccination with an autologous hemoderivative in changing tumor antigen library
Authors: E. Garcia-Giralt, E. Lasalvia-Prisco, S. Cucchi, J. Vazquez
Journal: Journal of Clinical Oncology (2004)

2594 Background. We have previously described a vaccination procedure with an Autologous Hemoderivative (AH) that in solid tumors, including breast cancer, inhibited the progressive disease condition, elicited Delayed Type Hypersensibility (DTH) and induced a tumor stroma modification in responder patients (E. Lasalvia-Prisco et al, Cancer Biology & Therapy, 2003; ASCO 2003). The present study describes the disease and DTH evolution in responder vaccinated patients. Methods. Thirty metastatic (1–3 sites), chemotherapy resistant (3-lines) breast cancer patients (Ages: 38–72 y.o.) in progressive disease (RECIST assessment) were included. Written informed consents and institutional ethical committee approval were accomplished. The included patients were vaccinated with AH with the procedure above referred. After 6 months, 11 patients were responders (Stable disease + Partial Remission) and DTH-positive response elicited by AH (≥ 5mm). When progressive disease reappeared, a second vaccination with a second AH was performed. Follow up of these 11 responder patients was analyzed (RECIST assessment and intradermal DTH-test elicited with the first and second AH). Results. Progressive Disease reappeared in 10 responder patients 7–14 months after vaccination. In these 10 patients, a second AH was freshly prepared and a second vaccination was performed. Previously to the second vaccination, DTH response elicited by intradermal test with the first AH persisted positive in 9, and it was negative in all 10 when it was performed with the second AH. Six month after the second vaccination with the new AH, a second Tumor-Growth response (Stable disease + Partial Remission) was evident in 8 patients and the DTH response elicited with the second AH was positive in 7 of them. ConclusionsResults are consistent with a tumor immuno-escape by changes in the neo-antigen library and the feasibility of re-vaccination with an updated AH containing neo-antigens delivered from the tumors to the blood. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration PharmaBlood, Inc.
Six versus nine cycles of paclitaxel-carboplatin as first-line chemotherapy in patients with newly diagnosed epithelial advanced ovarian cancer
Authors: B. Nayl, X. Durando, C. Pomel, P. Dubray, M. Mouret-Reynier, G. Le Bouedec, P. Gimbergues, P. Chollet, J. Dauplat, H. Cure
Journal: Journal of Clinical Oncology (2009)

e16535 Background: A multimodality approach with cytoreductive surgery and six courses of paclitaxel-platinum-based chemotherapy is actually the mainstay of treatment of Advanced Ovarian Cancer (AOC). This study was performed to determine retrospectively the efficacy of three additional cycles of paclitaxel-carboplatin (PC) in patients with AOC who had previously demonstrated chemosensitivity to six courses of this regimen. Methods: From January 2000 to August 2008, 125 epithelial AOC (FIGO stages IIIC and IV) were diagnosed in a single institution. After a cytoreductive surgery, 51 patients received six cycles of PC (PC 6 group), 57 received 9 (PC 9 group), and 17 experienced progressive disease during treatment. The chemotherapeutic regimen consisted of intravenous paclitaxel 175 mg/m 2 for a 3-hour infusion period and intravenous carboplatin AUC 5 every 3 weeks. Results: Median age was 62 years in PC6 group and 59.7 years in PC9. According to the FIGO criteria, 72.6% patients were in stage IIIC in group PC6 and 75.4% in group PC9. Except the patients who experienced refractory disease, complete clinical response at the end of chemotherapy was assessed in 71.4% patients in group PC6 and 71.9% in PC9 (p = 0.13). The median time to progression (TTP) was 26.2 months in PC6 and 29 months in PC9 (p = 0.5). The median overall survival (OS) was 106 months and 97 months respectively (p = 0.16). Conclusions: This retrospective study suggests that three cycles of consolidation chemotherapy with paclitaxel and carboplatin might not prolong duration of TTP or OS in AOC patients. No significant financial relationships to disclose.
<i>In situ</i> vaccine for low-grade lymphoma: Combination of intratumoral Flt3L and poly-ICLC with low-Dose radiotherapy.
Authors: Thomas Urban Marron, Adam Binder, Nina Bhardwaj, Seunghee Kim-Schulze, Tibor Keler, Tom Davis, Elizabeth Crowley, Andres M. Salazar, Joshua Brody
Journal: Journal of Clinical Oncology (2015)

TPS3105 Background: Lymphomas are the 5th most incident cancer in the U.S. and indolent non-Hodgkin's lymphoma (iNHL) are incurable with standard therapy. We previously completed three trials of ‘in situ vaccination’ - combining low-dose radiotherapy (XRT) with intratumoral administration of a TLR9 agonist (CpG). We demonstrated induction of tumor-specific CD8 T cell responses and clinical remissions of patients’ untreated sites of disease, lasting up to > 4 years. One limitation may have been the scarcity of intratumoral dendritic cells (DC). DC are uniquely able to endocytose dying (e.g. irradiated) tumor cells for cross-presentation to anti-tumor CD8 T cells. Methods: Flt3L– the predominant DC differentiation factor– induces tumor leukocyte infiltration and regression of lymphoma tumors pre-clinically and a new formulation of this cytokine -CDX-301- was shown to mobilize BDCA-1 and BDCA-3 DC subsets in an early phase trial. These DC subsets respond to several TLR agonists and cross-present antigens more effectively than plasmacytoid DC (the CpG-responsive DC subset). We initiated a phase I/II study of a new iteration of the in situ vaccine, adding Flt3L-priming and replacing the prior TLR9 agonist with the TLR3 agonist poly-ICLC (Fig 1A). The vaccine consists of: -intratumoral Flt3L administration to increase DC within the tumor -low-dose XRT to induce immunogenic tumor cell death and release tumor-associated antigens, and -intratumoral poly-ICLC administration to activate tumor antigen-loaded DC. The current study will assess two cohorts of patients (n = 15, each) with either previously untreated or relapsed/refractory iNHL to test the hypothesis that in situ vaccination will induce clinical remissions at distant (untreated) tumor sites. Eligibility: iNHL, either previously untreated or relapsed/refractory. Treatment: Intratumoral CDX-301 25ug/kg x 9 days. Local radiotherapy 2Gy x 2. Intratumoral poly-ICLC 2mg weekly x 8 weeks. Patients will have tumor (FNA) and blood collected for immune monitoring at weeks 0, 2, 4, 6, 8, 12 as well as pre treatment biopsy. Restaging CT scans will be done pretreatment and at week 12. Clinical trial information: NCT01976585. Clinical trial information: NCT01976585.
ASSOCIATION OF CIGARETTE SMOKING WITH PROCEDURAL COST OF LOWER EXTREMITY ENDOVASCULAR INTERVENTION
Authors: Haekyung Jeon-Slaughter, Erum Z. Whyne, Shirling Tsai, Ishita Tejani, Amutharani Baskar, Ehrin Armstrong, Nicolas Shammas, Gerardo Rodriguez, Mazen Abu-Fadel, Ian Cawich, Anand Prasad, Emmanouil Brilakis, Subhash Banerjee
Journal: Journal of the American College of Cardiology (2017)
Sym004, a novel strategy to target EGFR with an antibody mixture, in patients with advanced SCCHN progressing after anti-EGFR monoclonal antibody: A proof of concept study.
Authors: Jean-Pascal H. Machiels, Pol M. Specenier, Jürgen Krauss, Andreas Dietz, Marie-Christine Kaminsky, Yassine Lalami, Michael Henke, Ulrich Keilholz, Rainald Knecht, Niels Jorgen Ostergaard Skartved, Ivan David Horak, Mimi F Flensburg, Thomas Christoph Gauler
Journal: Journal of Clinical Oncology (2013)

6002 Background: Sym004 is a first-in-class drug mixture of two mAbs targeting non-overlapping epitopes on the EGFR. In preclinical models, Sym004 exhibited more pronounced EGFR internalization, degradation and tumor growth inhibition than cetuximab. Sym004 was investigated as monotherapy in palliative squamous cell carcinoma of the head and neck (SCCHN) patients (pts). Methods: SCCHN pts progressing after anti-EGFR mAbs for palliation were eligible. Documented clinical benefit (PR, CR or SD for at least 8 weeks according to RECIST) on an anti-EGFR mAb-containing regimen followed by disease progression during or within 12 weeks after treatment cessation was required. The primary endpoint of this multicentre single arm trial was centrally evaluated progression-free survival (PFS), estimated by median PFS and 24 week progression free rate. Secondary endpoints included objective tumor response, safety, biomarkers and pharmacokinetics. Pts received weekly iv infusions of 12 mg/kg Sym004 until disease progression. Tumor evaluation was performed week 6, 12 and every 8 weeks thereafter. Results: Based on the statistical hypothesis, 26 pts were included, of whom 23 had progressed while on anti-EGFR mAb treatment. One of 19 evaluable pts was HPV positive and no EGFRvIII mutation was detected in 21 evaluable pts. No anti-drug antibodies were detected. Independent central review of CT/MRI scans from 20 evaluable pts showed tumor shrinkage in 8 pts (% decrease in sum of the largest diameters: 6.5, 7.1, 9.6, 10.2, 11.3, 13.6, 16.7, 27.1) and 14 pts had SD as best overall response. Median PFS was 82 days (95% CI: 41, 140) and 24 week progression free rate was 12% (95% CI: 1, 39). During treatment 25/26 (96%) pts developed skin rash with ≥ grade 3 reported in 11/26 (42%) pts. Hypomagnesemia ≥ grade 3 was reported in 10/26 (38%) pts. Sym004 treatment resulted in a marked down regulation of EGFR in centrally reviewed biopsies from skin and tumors. Conclusions: Sym004 demonstrated clinical activity in heavily pretreated, predominately HPV negative pts with advanced SCCHN previously progressing on or after anti-EGFR mAbs. No unexpected toxicities were reported. Clinical trial information: NCT01417936.
Reduced Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes When Compared to Fludarabine and Busulfan Following Allogeneic Hematopoietic Cell Transplantation for Lymphoid Malignancies
Authors: Vanessa E Kennedy, Bipin N. Savani, John P. Greer, Adetola A. Kassim, Brian G Engelhardt, Stacey A. Goodman, Salyka M. Sengsayadeth, Wichai Chinratanalab, Madan H. Jagasia
Journal: Blood (2015)
PROLONGED INFLAMMATION LED TO AORTIC VALVE SCLEROSIS: LONGITUDINAL PET/CT STUDY
Authors: Won-Jang Kim, Seo-Won Choi, Junsu Chang, Daniel Min, Min-Kyu Kim, Woo-In Yang, Sang Hoon Kim, Jae Youn Moon, Jung Hoon Sung, In Jai Kim, Sang-Wook Lim, Dong-Hun Cha, Ji Young Lee, Soo Jin Jang, Dae Jung Kim
Journal: Journal of the American College of Cardiology (2017)
Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion for relapsed/refractory gastrointestinal (GI) adenocarcinoma.
Authors: Elisabeth De Vries, Volker Heinemann, Walter M. Fiedler, Thomas Seufferlein, Henk M.W. Verheul, Derk Jan De Groot, Jobst C. von Einem, Song Ren, Kam Cheung, Erik Rasmussen, Joerg Volkland, Gary Don Means, Andrea Kratzer, Andreas Wolf, Sabine Stienen
Journal: Journal of Clinical Oncology (2015)

TPS3097 Background: The bispecific CD19-directed CD3 T-cell engager (BiTE(R)) blinatumomab was recently approved by FDA as single-agent immunotherapy for patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL. The clinical activity of blinatumomab seen with 4-week infusion regimen provides rationale for BiTE administration as continuous intravenous infusion (cIV). Experience with an EpCAM-directed BiTE first-in-human study (FIH) suggests that in solid tumor indications dose levels achieving exposure comparable to 50% or even 90% of the maximal effective concentration in in vitro might be needed to observe substantial anti-tumor activity translating into objective response (Fiedler et al, J Clin Oncol 30, 2012, abstr 2504). The CEA-directed BiTE (MEDI-565, AMG 211) inhibited the growth of CEA-expressing cancer cells in various cancer models in the presence of CD3+ T-cells and has been explored as an intermittent 3-hour infusion for 5 subsequent days in a FIH study (NCT01284231). The present study aims at cIV AMG 211 administration that will result in lower Cmax concentrations compared to intermittent infusions. The steady state levels with potential effective exposure should range above a threshold level required for anti-tumor activity for a prolonged period of time. The therapeutic index may be improved by reduction of adverse events attributable to a higher Cmaxof discontinuous administration but other adverse events due to prolonged exposure will need to be assessed. Methods: Approximately 34 patients with relapsed/refractory GI adenocarcinomas will be treated with AMG 211 for 7, 14 or 28 days at 200-6,400 µg/day cIV infusion in repeated cycles with 2-week breaks until confirmed disease progression, occurrence of a dose-limiting toxicity (DLT) or discontinuation for other reasons. A toxicity probability interval Bayesian model will guide dose escalation after a first DLT. Study objectives include evaluation of safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy. Cohort 1 has been completed without DLT and cohort 2 started enrollment in January 2015. ClinicalTrials.gov Identifier: NCT02291614 Clinical trial information: NCT02291614.
Calvariae-Resident Osteomacs That Are Phenotypically and Functionally Distinct from Marrow-Derived Macrophages Interact with Megakaryocytes to Regulate Hematopoietic Stem Cell Function
Authors: Safa F Mohamad, Linlin Xu, Himes R Evan, Hao Wu, Marta Alvarez, Paul Childress, Korbin Davis, Melissa Kacena, Edward F. Srour
Journal: Blood (2016)
CARDIAC ATROPHY: A NOVEL MECHANISM FOR DUCHENNE MUSCULAR DYSTROPHY (DMD)-ASSOCIATED CARDIOMYOPATHY
Authors: Shaida Khan, Daniel Cheeran, Sonia Garg, Justin Grodin, Robert Morlend, Faris Araj, Alpesh Amin, Jennifer Thibodeau, Mark Drazner, Pradeep Mammen
Journal: Journal of the American College of Cardiology (2017)
IMPROVED DIAGNOSIS OF DETECTION OF LATE ENHANCEMENT IN LEFT VENTRICULAR MYOCARDIUM USING 2ND GENERATION 320-SLICE CT RECONSTRUCTED WITH FIRST IN NON-ISCHEMIC CARDIOMYOPATHY
Authors: Nobusada Funabashi, Hiroyuki Takaoka, Koya Ozawa, Masae Uehara, Koichi Sano, Yoshio Kobayashi
Journal: Journal of the American College of Cardiology (2017)
Erratum: Activation of neutrophils by autocrine IL-17A–IL-17RC interactions during fungal infection is regulated by IL-6, IL-23, RORγt and dectin-2
Authors: Patricia R Taylor, Sanhita Roy, Sixto M Leal, Yan Sun, Scott J Howell, Brian A Cobb, Xiaoxia Li, Eric Pearlman
Journal: Nature Immunology (2015)
Low-Dose Bexarotene and Phototherapy or Interferon Alfa-2a in the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma
Authors: Brady Beltran, Antonio Paredes, Celia Moises, Gadwin Sanchez, Luis Riva, Fernando Hurtado, Renzo Salas, Jorge Castillo
Journal: Blood (2008)
Prognostic role of microRNA polymorphisms in advanced gastric cancer patients.
Authors: Linnea Stenholm, Jan Stoehlmacher-Williams, Salah-Eddin Al-Batran, Nicole Heussen, Sema Akin, Claudia Pauligk, Sylvia Lehmann, Tina Senff, Gerhard Ehninger, Tim H. Brummendorf, Eray Goekkurt
Journal: Journal of Clinical Oncology (2012)

10552 Background: As little is known about the impact of microRNA (mir) polymorphisms on prognosis of advanced gastric cancer (AGC) we sought to determine their impact on overall survival (OS) in these patients (pts). Methods: Pts were treated with either 5-fluorouracil, leucovorin and oxaliplatin (FLO) or with additional docetaxel (FLOT) in frame of a phase III or 3 phase II trials of the Arbeitsgemeinschaft Internistische Onkologie. All pts consented genetic analyses. DNA was extracted from whole blood samples (n=515) and polymorphisms of mir26a1 (rs7372209), mir27a (rs895819), mir100 (rs1834306), mir125a (rs12975333), mir146a (rs2910164), mir196a2 (rs11614913), mir219-1 (rs107822) and mir423 (rs6505162) were genotyped using PCR-based methods. Hetero- and homozygous variant genotypes were grouped versus homozygous wild type genotypes. Selection of clinical and genetic parameters for the final multivariate model was based on univariate and multivariate Cox-regression analyses with a cut-off value of p &lt; 0.25 and included 498 pts. Results: Median age was 67 (range 23 to 86) years. 42% were treated with FLO and 58% with FLOT with a median OS of 14 months. Multivariate analyses revealed following associations: Genetic factors significantly associated with OS were mir26a1 variant genotypes (HR 1.3 [95%CI (1.01;1.6), p=.025]), mir27a variant genotypes (HR 1.3 [95%CI (1.01;1.6), p=.036]) and mir196a2 variant genotypes (HR 0.8 [95%CI (0.6;0.99), p=.046]). Clinical factors with significant impact on OS were ECOG 2 performance status (HR 1.9 [95%CI (1.3;2.8), p=.002]), curative surgery of advanced disease (HR 0.3 [95%CI (0.1;0.5), p&lt;.001]) and locally advanced disease (HR 0.5 [95%CI (0.3;0.7), p&lt;.001]). Combined analyses of the identified adverse genotypes of mir26a1, mir27a and mir196a2 resulted in a median OS of 9, 13, 14 and 17 months for pts with 0 (n=72), 1 (n=193), 2 (n=171) and 3 (n=54) adverse genotypes (p=.029), respectively. Conclusions: In addition to established clinical factors, mir26a1, mir27a and mir196a2 polymorphisms were significantly associated with OS. Our data suggest a strong impact of these mir polymorphisms on prognosis in AGC and might be of help for a better guidance of treatment decisions.
R115777(tipifarnib) Improves Early Survival when Used As Maintenance Therapy for Elderly or Relapsed/Refractory Patients with Acute Myelogenous Leukemia in Remission
Authors: Selina Luger, Lynette Zickl, Elisabeth Paietta, Rhett P Ketterling, Hillard M Lazarus, Witold Rybka, Mark R Litzow, Jacob M Rowe, Richard A. Larson, Martin S. Tallman
Journal: Blood (2012)
IMPACT OF A SWITCH FROM DUAL ANTIPLATELET THERAPY TO SINGLE ANTIPLATELET THERAPY IN DIABETES AND NON-DIABETES POST ACS: INSIGHTS FROM THE EPICOR AND EPICOR-ASIA STUDIES
Authors: Frans J.J. Van de Werf, Yaling Han, Xavier Rossello, Yong Huo, Stuart J. Pocock, Yi Li, Jie Jiang, Ana Maria Vega, Jesús Medina, Héctor Bueno
Journal: Journal of the American College of Cardiology (2017)
Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubucin and Rituximab (da-EPOCH-R) Vs Rituxan, Cyclophosphamide, Doxorubucin, Vincristine and Prednisone (R-CHOP) As First Line Treatment for Diffuse Large B-Cell Lymphoma (DLBCL)
Authors: Parikshit Padhi, Abhishek Chilkulwar, Cyrus Khan, Monank Patel, John Lister, Xiaoqin Tang
Journal: Blood (2016)